Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
Study Identifier:
C11-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab (Soliris®)
Date
Jul 2011 - Jan 2012
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2+ years
Requirements Information
Sex
Female & Male
Age
2+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab (Soliris®)
Date
Jul 2011 - Jan 2012
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2+ years years
Requirements Information
Protocol Summary
This protocol is designed to collect safety and efficacy data on patients that have been or will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in Germany.
Trial Locations
Location
Status
Location
Bielefeld, Germany, 33615
Status
N/A
Location
Bielefeld, Germany, 33617
Status
N/A
Location
Bonn, Germany, 53127
Status
N/A
Location
Bremen, Germany, 28177
Status
N/A
Location
Bremerhaven, Germany, 27574
Status
N/A
Location
Essen, Germany, 45147
Status
N/A